Meeting Coverage
ACAAI
American College of Allergy, Asthma & Immunology
Latest ACAAI Meeting Coverage
Off-label use along with antihistamines improved activity, itch, and wheal count scores
Remibrutinib demonstrated superiority over placebo in both the REMIX-1 and -2 trials
No benefit for the privately insured in trial, but participants on Medicaid had lower risk
ChatGPT sometimes gave opposite answers, and clinicians themselves didn't always agree
In a survey, 42% of PCPs said they were "not familiar" with biologic therapies for asthma
Open-label extension of EPITOPE trial shows increased tolerance at 24 months
Patients taking the oral mucosal immunotherapy reported only minor adverse effects
Monoclonal antibodies, BTK inhibitor alleviate symptoms when antihistamines fall short
More kids had responses, decreased symptom severity, versus those who received placebo
Pharmacokinetics in healthy cohort looks promising
No safety concerns reported and swelling attacks declined
PTAH, already approved for those ages 4-17, also attenuated the sensitivity in younger children
Albuterol-budesonide also reduced time with severe exacerbations
Implementation barriers included parental fears, pediatrician time crunch
Latest Allergy & Immunology Meeting Coverage
-
ACAAI: American College of Allergy, Asthma & Immunology
October 2024
-
AAAAI: American Academy of Allergy Asthma & Immunology
February 2024
-
ACIP: Advisory Committee on Immunization Practices
October 2022
-
ICD: International Congress of Dermatology
May 2009